1. AGA suggests against using thiopurine monotherapy to induce remission in patients with moderately severe Crohn’s disease.
2. AGA suggests against using methotrexate to induce remission in patients with moderately severe Crohn’s disease.
3. AGA recommends using anti-tumor necrosis factor-α (anti-TNF-α) drugs to induce remission in patients with moderately severe Crohn’s disease.
4. AGA recommends using anti-TNF-α monotherapy over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn’s disease.
5. AGA recommends using anti-TNF-α drugs in combination with thiopurines over thiopurine monotherapy to induce remission in patients who have moderately severe Crohn’s disease.
6. AGA suggests using anti-TNF-α drugs in combination with thiopurines over anti-TNF-α drug monotherapy to induce remission in patients who have moderately severe Crohn’s disease.
7. AGA recommends using thiopurines over no immunomodulator therapy to maintain a corticosteroid-induced remission in patients with Crohn’s disease.
8. AGA suggests using methotrexate over no immunomodulator therapy to maintain corticosteroid-induced remission in patients with Crohn’s disease.
9. AGA recommends using anti-TNF-α drugs over no anti-TNF-α drugs to maintain corticosteroid- or anti-TNF-α-induced remission in patients with Crohn’s disease.
10. AGA makes no recommendation for or against the combination of an anti-TNF-α drug and a thiopurine versus an anti-TNF-α Drug alone to maintain remission induced by a combination of these drugs in patients with Crohn’s disease.
